Viracta Therapeutics Stock Market Value
| VIRX Stock | USD 0.15 0.01 6.25% |
| Symbol | Viracta |
Viracta Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viracta Therapeutics. If investors know Viracta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viracta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Return On Assets (0.57) | Return On Equity (2.09) |
The market value of Viracta Therapeutics is measured differently than its book value, which is the value of Viracta that is recorded on the company's balance sheet. Investors also form their own opinion of Viracta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viracta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viracta Therapeutics' market value can be influenced by many factors that don't directly affect Viracta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viracta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viracta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viracta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Viracta Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Viracta Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Viracta Therapeutics.
| 10/22/2024 |
| 11/21/2024 |
If you would invest 0.00 in Viracta Therapeutics on October 22, 2024 and sell it all today you would earn a total of 0.00 from holding Viracta Therapeutics or generate 0.0% return on investment in Viracta Therapeutics over 30 days. Viracta Therapeutics is related to or competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, Transcode Therapeutics, and Quoin Pharmaceuticals. Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associa... More
Viracta Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Viracta Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Viracta Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 25.82 | |||
| Value At Risk | (8.00) | |||
| Potential Upside | 4.55 |
Viracta Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viracta Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Viracta Therapeutics' standard deviation. In reality, there are many statistical measures that can use Viracta Therapeutics historical prices to predict the future Viracta Therapeutics' volatility.| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.76) | |||
| Total Risk Alpha | (1.41) | |||
| Treynor Ratio | 0.5629 |
Viracta Therapeutics Backtested Returns
Viracta Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.19, which indicates the firm had a -0.19% return per unit of risk over the last 3 months. Viracta Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Viracta Therapeutics' Variance of 20.5, risk adjusted performance of (0.14), and Coefficient Of Variation of (508.15) to confirm the risk estimate we provide. The entity has a beta of -1.6, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Viracta Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Viracta Therapeutics is expected to outperform it. At this point, Viracta Therapeutics has a negative expected return of -0.86%. Please make sure to validate Viracta Therapeutics' treynor ratio and rate of daily change , to decide if Viracta Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.92 |
Excellent predictability
Viracta Therapeutics has excellent predictability. Overlapping area represents the amount of predictability between Viracta Therapeutics time series from 22nd of October 2024 to 6th of November 2024 and 6th of November 2024 to 21st of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Viracta Therapeutics price movement. The serial correlation of 0.92 indicates that approximately 92.0% of current Viracta Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.92 | |
| Spearman Rank Test | 0.83 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Viracta Therapeutics lagged returns against current returns
Autocorrelation, which is Viracta Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Viracta Therapeutics' stock expected returns. We can calculate the autocorrelation of Viracta Therapeutics returns to help us make a trade decision. For example, suppose you find that Viracta Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Viracta Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Viracta Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Viracta Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Viracta Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Viracta Therapeutics Lagged Returns
When evaluating Viracta Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Viracta Therapeutics stock have on its future price. Viracta Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Viracta Therapeutics autocorrelation shows the relationship between Viracta Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Viracta Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.